Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.

Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC.

J Control Release. 2019 Sep 28;310:47-57. doi: 10.1016/j.jconrel.2019.08.006. Epub 2019 Aug 7.

PMID:
31400383
2.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC.

Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5.

PMID:
30952988
3.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.

Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.

4.

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.

Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA.

MAbs. 2017 Jan;9(1):58-67. doi: 10.1080/19420862.2016.1259047. Epub 2016 Nov 17.

5.

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

Zhang K, Geddie ML, Kohli N, Kornaga T, Kirpotin DB, Jiao Y, Rennard R, Drummond DC, Nielsen UB, Xu L, Lugovskoy AA.

MAbs. 2015;7(1):42-52. doi: 10.4161/19420862.2014.985933.

6.

Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.

Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, Hadaczek P, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW.

Nanomedicine (Lond). 2014 Jul;9(14):2099-108. doi: 10.2217/nnm.13.201. Epub 2014 Feb 4.

PMID:
24494810
7.

Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.

Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW.

Nanomedicine (Lond). 2013 Dec;8(12):1913-25. doi: 10.2217/nnm.12.209. Epub 2013 Apr 30.

PMID:
23631502
8.

Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD.

Neuro Oncol. 2013 Feb;15(2):189-97. doi: 10.1093/neuonc/nos305. Epub 2012 Dec 21.

9.

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC.

Methods Enzymol. 2012;502:139-66. doi: 10.1016/B978-0-12-416039-2.00007-0.

PMID:
22208985
10.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD.

Neuro Oncol. 2011 Dec;13(12):1288-95. doi: 10.1093/neuonc/nor139. Epub 2011 Sep 27.

11.

Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, Yamashita Y, Krauze MT, Forsayeth J, Noble CO, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS.

Neuro Oncol. 2010 Sep;12(9):928-40. doi: 10.1093/neuonc/noq046. Epub 2010 May 20.

12.

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB.

J Control Release. 2010 Jan 4;141(1):13-21. doi: 10.1016/j.jconrel.2009.08.006. Epub 2009 Aug 15.

PMID:
19686789
13.

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC.

Cancer Chemother Pharmacol. 2009 Sep;64(4):741-51. doi: 10.1007/s00280-008-0923-3. Epub 2009 Jan 30.

14.

Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.

Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, Tseng YL, Hong K, Kirpotin DB.

J Pharmacol Exp Ther. 2009 Jan;328(1):321-30. doi: 10.1124/jpet.108.141200. Epub 2008 Oct 23.

15.

Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW.

Nano Lett. 2008 Sep;8(9):2851-7. doi: 10.1021/nl801488u. Epub 2008 Aug 20.

PMID:
18712930
16.

Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.

Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, Yamashita Y, Krauze M, Noble CO, Drummond D, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS.

J Neurosurg. 2008 May;108(5):989-98. doi: 10.3171/JNS/2008/108/5/0989.

PMID:
18447717
17.

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB.

J Pharm Sci. 2008 Nov;97(11):4696-740. doi: 10.1002/jps.21358. Review.

PMID:
18351638
18.

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B.

Mol Cancer Ther. 2008 Mar;7(3):569-78. doi: 10.1158/1535-7163.MCT-07-2132. Epub 2008 Mar 4.

19.

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B.

Mol Cancer Ther. 2007 Oct;6(10):2737-46.

20.

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS.

Neuro Oncol. 2007 Oct;9(4):393-403. Epub 2007 Jul 24.

21.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD.

J Mol Biol. 2007 Aug 24;371(4):934-47. Epub 2007 May 10.

22.

Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA.

Mol Immunol. 2007 Jul;44(15):3777-88. Epub 2007 May 10.

23.

Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N 4th, Park JW, Marks JD, Benz CC, Kirpotin DB.

Mol Pharm. 2006 Nov-Dec;3(6):726-36.

PMID:
17140260
24.

A novel assay for monitoring internalization of nanocarrier coupled antibodies.

Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD.

BMC Immunol. 2006 Oct 2;7:24.

25.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.

Cancer Res. 2006 Jul 1;66(13):6732-40.

26.

Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS.

Neuro Oncol. 2006 Jul;8(3):205-14. Epub 2006 May 24.

27.

Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases.

Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB.

Biochim Biophys Acta. 2006 Apr;1758(4):429-42. Epub 2006 Apr 17.

28.

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB.

Cancer Res. 2006 Mar 15;66(6):3271-7.

29.

Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.

Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW.

Cancer Res. 2006 Mar 1;66(5):2801-6.

30.

Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery.

Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS.

J Neurosci Methods. 2006 Jun 30;154(1-2):225-32. Epub 2006 Feb 10.

PMID:
16472868
31.

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW.

Cancer Res. 2005 Dec 15;65(24):11631-8.

32.

Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K.

Gene Ther. 2006 Apr;13(7):646-51.

PMID:
16341056
33.

Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain.

Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS.

Exp Neurol. 2005 Dec;196(2):381-9. Epub 2005 Sep 28.

PMID:
16197944
34.

Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.

Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB.

Biotechnol Prog. 2005 Jan-Feb;21(1):221-32.

PMID:
15903261
35.

Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL.

Biotechnol Prog. 2005 Jan-Feb;21(1):205-20.

PMID:
15903260
36.

Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC.

Clin Cancer Res. 2005 May 1;11(9):3392-401.

37.

Clinical development of histone deacetylase inhibitors as anticancer agents.

Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC.

Annu Rev Pharmacol Toxicol. 2005;45:495-528. Review.

PMID:
15822187
38.

Emerging antibody-based HER2 (ErbB-2/neu) therapeutics.

Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC.

Breast Dis. 2000;11:113-24.

PMID:
15687597
39.

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC.

Expert Opin Ther Targets. 2004 Aug;8(4):335-53. Review.

PMID:
15268628
40.

Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.

Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS.

J Neurooncol. 2004 May;68(1):1-9.

PMID:
15174514
41.

Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging.

Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS.

Cancer Res. 2004 Apr 1;64(7):2572-9.

42.

Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.

Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD.

Cancer Res. 2004 Jan 15;64(2):704-10.

43.

Liposome-based approaches to overcome anticancer drug resistance.

Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW.

Drug Resist Updat. 2003 Oct;6(5):271-9. Review.

PMID:
14643297
44.

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW.

Cancer Res. 2003 Jun 15;63(12):3154-61.

45.

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD.

Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118.

46.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.

Clin Cancer Res. 2002 Apr;8(4):1172-81.

47.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
48.

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC.

Biochem Biophys Res Commun. 2001 Jan 12;280(1):274-9.

PMID:
11162510
49.

Liposome targeting to tumors using vitamin and growth factor receptors.

Drummond DC, Hong K, Park JW, Benz CC, Kirpotin DB.

Vitam Horm. 2000;60:285-332. Review.

PMID:
11037627
50.

Anti-HER2 immunoliposomes for targeted drug delivery.

Hong K, Kirpotin DB, Park JW, Shao Y, Shalaby R, Colbern G, Benz CC, Papahadjopoulos D.

Ann N Y Acad Sci. 1999;886:293-6. Review. No abstract available.

PMID:
10667243

Supplemental Content

Loading ...
Support Center